Affiliations: [a]
University of Washington, School of Pharmacy, Seattle, WA, USA
| [b]
University of Washington, School of Public Health, Seattle, WA, USA
| [c]
University of Washington, School of Medicine, Seattle, WA, USA
| [d]
Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
Correspondence:
[*]
Correspondence to: Zachary A. Marcum, PharmD, PhD, Department of Pharmacy, School of Pharmacy, University of Washington, 1959 NE Pacific St, Box 357630, Seattle, WA 98195, USA. Tel.: +1 206 685 2559; Fax: +1 206 543 3835; E-mail: [email protected].
Abstract: We administered a mixed-method survey to 1,661 patients in a large health system to assess preferences toward antihypertensive use for dementia prevention. If a specific antihypertensive medication was shown to prevent or delay dementia, the vast majority (>90%) of respondents currently taking an antihypertensive reported that they would be willing to take that specific antihypertensive starting as early as mid-life. Concerns reported were potential side effects, lack of evidence of effectiveness, blood pressure being normal or low, and medication cost. Analysis of free-text responses revealed themes of concerns regarding evidence of effectiveness and health priorities.
